Eloxx Pharmaceuticals, Inc. Common Stock ELOX

$18.76 -1.63% at last close

Analyst Consensus

Consensus Rating
Buy (2 Buy · 0 Hold · 0 Sell)
Average Price Target
$41.50
Implied Upside
+121.2%
Price Target Range
$40.00 – $43.00
Analysts (12 mo)
2

Recent Analyst Actions

DateFirmActionRatingPrice Target
2026-07-22
LifeSci CapitalRami Katkhuda
Initiates coverage on Outperform $40
2026-07-20
GuggenheimVamil Divan
Initiates coverage on Buy $43
2023-07-11
OppenheimerHartaj Singh
Maintains Outperform $50 → $55
2023-04-06
OppenheimerHartaj Singh
Reiterates Outperform $50
2022-05-23
Piper SandlerEdward Tenthoff
Maintains Overweight $160 → $60
2022-05-09
HC Wainwright & Co.Andrew Fein
Maintains Neutral $40 → $20
2021-12-17
OppenheimerHartaj Singh
Initiates coverage on Outperform $160
2021-11-18
HC Wainwright & Co.Andrew Fein
Maintains Neutral $80 → $40
2021-11-11
HC Wainwright & Co.Andrew Fein
Maintains Neutral $120 → $80
2021-06-30
MizuhoDifei Yang
Initiates coverage on Buy $124
2021-05-27
B. Riley SecuritiesMayank Mamtani
Initiates coverage on Buy $200
2020-06-11
CitigroupJoel Beatty
Downgrades Buy → Neutral $440 → $160
2020-05-08
Janney Montgomery Scott
Maintains Buy $520 → $400
2020-03-06
HC Wainwright & Co.Andrew Fein
Reiterates Neutral $400 → $120
2019-09-06
Janney Montgomery Scott
Initiates coverage on Buy
2019-05-15
Canaccord Genuity
Maintains Buy $800 → $680
2018-12-24
HC Wainwright & Co.Andrew Fein
Initiates coverage on Neutral $400
2018-07-03
CitigroupJoel Beatty
Initiates coverage on Buy
2018-06-29
Canaccord Genuity
Initiates coverage on Buy $960
2018-06-26
SunTrust Robinson Humphrey
Initiates coverage on Buy $1040
2018-05-01
Piper SandlerEdward Tenthoff
Initiates coverage on Overweight $800

Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.

Key Stats

Last Close
$18.76
Market Cap
$64.47 million
52-Week Range
$0.00 $19.96
Average Volume
60K shs

Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.